Best Pain Management Companies in United States
The 338 best Pain Management companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Assertio.
Ranking the best Pain Management companies in the United States by disclosed equity funding, this directory tracks 338 ventures that have collectively pulled in $6.1 billion. That's real capital committed to a problem with enormous clinical weight: reducing postoperative pain, cutting opioid consumption, and lowering hypotensive events at scale. Saluda Medical leads the field at $400 million raised, with SPR close behind at $180 million and Quoin Pharmaceuticals at $106 million. As shown in 2017 research on surgical pain protocols, the pressure to move patients off opioids has only sharpened the investment case. HHS and NIH are among the most active backers here, which tells you something about how much regulatory and public-health weight this sector carries.
So what does the funding distribution actually reveal? No unicorns yet, but the gap between the top tier and the rest is wide. Allay Therapeutics ($102M) and Centrexion ($66M) round out a meaningful mid-pack, while most of the 338 tracked companies are still early. I'd note that global operators like Medtronic and Zynex Inc. are gaining ground in the same space, which keeps competitive pressure real for U.S. pure-plays. The demand isn't going anywhere. The question is which companies can convert clinical necessity into durable revenue.
- Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Roun
Ranked: Best Pain Management companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Assertio Developer of drugs to treat pain and other neurological diseases | $906M | 135 mo ago | 29 29 → 65 (+124%) | — | — | — | — |
| 2 | Saluda Medical Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment 62Funding top 14%Moat top 31%News top 39%Growth top 42% All 8 signals ▾Fundingtop 14% Moattop 31% Newstop 39% Growthtop 42% Markettop 44% Techtop 45% Talentbottom 49% Globalbottom 43% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 62/100 | $400M | 7 mo ago | 327 | Jim Schuermann CEO | 3 signals ▲50% IPO | — | 1 launch |
| 3 | Avanos Manufacturer of medical devices for pain management and enteral feeding | $250M | 89 mo ago | 5,003 | Joe Woody CEO | — | — | — |
| 4 | Nalu Medical Developer of a neurostimulation system for managing intractable chronic pain | $231M | 29 mo ago | 166 | Keegan Harper Founder | — | 161 patents Implantable neuromodulation devices delivering advanced stimulation waveforms for pain therapy | — |
| 5 | Iroko European real estate investment expert, offering accessible and responsible savings solutions | $215M | 118 mo ago | 4 | — | — | — | 1 partnership |
| 6 | SPR Developer of non-implant peripheral nerve stimulation systems for pain management | $180M | 14 mo ago | — | Maria Bennett Founder & CEO | — | — | 2 launchs · 1 award |
| 7 | Xanodyne Pharmaceuticals Developer of drugs for women's health and pain management | $176M | 199 mo ago | 6 | — | — | — | — |
| 8 | SPR Therapeutics Peripheral nerve stimulation therapy for treating pain | $174M | 28 mo ago | 198 | Maria E Bennett Founder & CEO | — | 220 patents Implantable neurostimulation systems for chronic pain and back pain relief | — |
| 9 | Eliem Therapeutics Developer of non-opioid therapies for treating chronic pain | $171M | 61 mo ago | 30 | Valerie Morisset Co-Founder | — | — | — |
| 10 | Zogenix Developing drug delivery systems for treatment of CNS diseases | $149M | 104 mo ago | 159 | Bret Megargel Co-Founder | — | 151 patents Novel CNS and mitochondrial therapeutics: prodrugs, formulations, and seizure‑related compounds. | — |
| 11 | Myoscience Non-opioid pain relief treatment using advanced cold technology | $148M | 91 mo ago | 687 | — | — | 167 patents Patents concentrated in health & consumer products | — |
| 12 | Zosano Pharma Developer of transdermal drug delivery systems for a broad range of therapeutic indications | $147M | 92 mo ago | 40 | — | — | — | — |
| 13 | Trevena Developer of GPCR ligand technology based therapeutics for cardiovascular diseases and pain | $119M | 29 mo ago | 35 | — | — | 233 patents Patents concentrated in chemistry & materials | — |
| 14 | ShiraTronics Developer of a neuromodulating device for treating migraine | $108M | 21 mo ago | 29 | — | — | 67 patents Implantable neurostimulation devices for headache relief with wireless charging and communication | — |
| 15 | Quoin Pharmaceuticals Developer of small molecule-based therapeutics for the treatment of CNS and dermatology diseases 45News top 22%Growth top 25%Funding top 29%Talent top 33% All 7 signals ▾Newstop 22% Growthtop 25% Fundingtop 29% Talenttop 33% Techtop 44% Globalbottom 32% Marketbottom 16% News: 9 BI events in 12 mo (of 45 tracked, 7 types) · +125% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $106M | 8 mo ago | 4 | Michael Myers Co-Founder Quoin Pharmaceuticals | 9 signals ▲125% Earnings · Leadership · Announcements | — | 1 launch |
| 16 | Collegium Pharma Developer of therapeutics for chronic pain management | $103M | 91 mo ago | 197 | Michael Heffernan Founder &CEO | 14 signals ▼53% Earnings · Announcements · M&A | — | — |
| 17 | Allay Therapeutics Developer of drugs for post-surgical pain management 42Funding top 18%Moat top 39%Market bottom 44%Global bottom 38% All 5 signals ▾Fundingtop 18% Moattop 39% Marketbottom 44% Globalbottom 38% Newsbottom 21% Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $102M | 12 mo ago | 50 | — | — | — | — |
| 18 | Heron Therapeutics Pharmaceutical company focused on acute care and oncology with innovative therapies | $86M | 34 mo ago | 21 | — | 13 signals Earnings · Leadership · Capital raise | 202 patents Advanced drug delivery devices and pharmaceutical formulation technologies for injectable therapies | 2 job openings |
| 19 | BioQ Pharma Ready-to-use connect-and-go systems transforming infusible medicines for safer, simpler delivery | $85M | 77 mo ago | 15 | — | — | — | — |
| 20 | AEON BioPharma Provider of bio-therapeutics to treat nervous system-related conditions | $84M | 46 mo ago | 9 | Marc Forth President and Chief Executive Officer | 8 signals ▲167% Earnings · Funding · Regulatory | 78 patents Botulinum toxin therapeutics for migraine, pain, autonomic and cardiovascular disorders | — |
| 21 | eNeura Developer of a transcranial magnetic stimulation device for pain relief | $71M | 76 mo ago | 17 | — | — | 21 patents Non‑invasive magnetic brain stimulation therapies for migraine and neuropathic pain | — |
| 22 | Centrexion Developer of drugs for chronic pain management | $66M | 12 mo ago | 14 | Sol Barer Founder & Chairman | — | — | — |
| 23 | Nufabrx Provider of a wearable fabric with therapeutic value for pian managmenet | $43M | 56 mo ago | 32 | Jordan Schindler Founder & CEO | — | — | — |
| 24 | Neumentum Developing non-opioid pain management solutions for acute and chronic pain | $41M | 37 mo ago | 8 | Joseph Pergolizzi Co-Founder | — | 5 patents Topical analgesic and anti-inflammatory pharmaceutical formulations | — |
| 25 | OcuTerra Therapeutics Developer of eye drop to treat diabetic eye disease | $40M | 30 mo ago | 4 | — | — | — | — |
| 26 | EicOsis Developing safer pain and inflammation treatments by restoring the body's natural healing | $31M | 14 mo ago | 14 14 → 7 (-50%) | Robert Gregoire Co-Founder & CEO | — | 24 patents Solid-form pharmaceutical innovations for epoxide hydrolase and kinase inhibitor therapies | — |
| 27 | SiteOne Therapeutics Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain. | $24M | 13 mo ago | — | John Mulcahy Co-Founder & CEO | — | — | — |
| 28 | Protega Pharmaceuticals Provider of specialty pharmaceutical company that focuses on responsible pain management | $16M | 14 mo ago | — | Stefan Aigner CEO | — | — | — |
| 29 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | 10 | Prashant Mali Co-Founder | — | — | — |
| 30 | Modulight Biotherapeutics Developer of an optogenetic platform targeting pathological neural activity to restore balance | $12M | 7 mo ago | — | Ofer Yizhar Co-Founder & CSO | — | — | 1 award |
| 31 | NanoVibronix Provider of ultrasound therapy devices for multiple health purposes | $11M | 11 mo ago | 10 | Harold Jacob CEO | — | 35 patents Ultrasonic surface acoustic wave devices for skin therapy, drug delivery, and biofilm control | — |
| 32 | Aponia Laboratories Developer of topical treatment for muscle soreness | $10M | 25 mo ago | 1 | Robert Boolbol Co-Founder | — | 31 patents Transdermal ibuprofen drug delivery systems for topical pain relief | — |
| 33 | Raft Pharmaceuticals Developer of therapeutics to treat neuroinflammation | $10M | 14 mo ago | — | Tony Yaksh Co-Founder | — | — | — |
| 34 | Cytogel Pharma Provider of an analgesic product candidate and polymer and hydrogel drug delivery platform technologies | $9M | 8 mo ago | 7 | C. Maglaris CEO | — | — | — |
| 35 | InSitu Biologics Developer of multi-phase prolonged release drug delivery platform for localized treatments | $8M | 7 mo ago | 7 | Bill Taylor Co-Founder & Chief Science Officer | — | 29 patents Patents concentrated in health & consumer products | — |
| 36 | Rebel Medicine Developer of therapeutics for pain management | $7M | 16 mo ago | 9 | — | — | 18 patents Analgesic drug formulations, especially oil‑in‑water emulsions for pain relief | — |
| 37 | Surf Developer of non-invasive ultrasound neuromodulation platform for chronic inflammatory disorders | $6M | 2 mo ago | — | Nishant Doctor Co-Founder & CEO | — | 14 patents Specialized three-toed and water footwear design and manufacturing | — |
| 38 | Nice Recovery Systems Developer of a cold compression therapy device | $6M | 21 mo ago | 10 | Michael Ross Founder | — | — | 1 launch |
| 39 | MAXONA Developer of therapeutics for the treatment of pain | $6M | 12 mo ago | 1 | Shawn Fatholahi CEO & President | — | — | — |
| 40 | Young BioPharma Developer of therapeutics for pain | $4M | 13 mo ago | — | Young Shen Founder | — | — | — |
| 41 | Amalgent Developer of therapeutics for pain management | $3M | 22 mo ago | 2 | Sam Tetlow | — | — | — |
| 42 | Elysium Therapeutics Developing innovative solutions to combat opioid overdose and reduce opioid abuse | $2M | 4 mo ago | 2 | Alex Sturmer President | — | — | — |
| 43 | Virpax Pharmaceuticals Developer of meter-dosed spray & liposomal gels for topical pain management | $1M | 16 mo ago | 7 | — | — | — | — |
| 44 | Adolore Biotherapeutics Developer of non-opioid analgesics for the treatment of pain | $1M | 9 mo ago | — | Joseph Glorioso Founder | — | — | — |
| 45 | Neuroglide Developer of automated lymphatic drainage therapy for pain relief and lymphatic health | $852K | 13 mo ago | — | Irene Waldridge Founder & CEO & CTO | — | — | — |
| 46 | SphenoCath Precision intra-nasal medicine delivery device improving patient outcomes | $800K | 21 mo ago | — | — | — | — | — |
| 47 | WinSanTor Developing nerve-regenerating treatments for peripheral neuropathy, improving patient lives | $783K | 14 mo ago | 5 | Nigel Calcutt Co-Founder | — | 25 patents Topical pharmaceutical formulations for peripheral neuropathy pain and sexual sensory disorder treatment. | — |
| 48 | Exxel Pharma Developer of drugs for pain management | $600K | 18 mo ago | 3 | Soren Mogelsvang CEO & President | — | — | — |
| 49 | Sen-Jam Developer of repurposed drugs to treat pain, inflammation and toxin-induced conditions | $480K | 16 mo ago | 10 | Jim Iversen Co-Founder CEO | — | — | — |
| 50 | Akelos Biotechnology firm pioneering non-opioid neuropathic pain treatments | $320K | 3 mo ago | 4 | Steven Fox Founder | — | — | — |
Top 12 Pain Management companies in United States
#1
Public · Bloomington, Minnesota · founded 2010 · 327 employees$400Mraised▾
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment. It offers a system that measures and records neural activation characteristics. The system quantifies stimulation levels to a clinician-defined target, continuously comparing neural activation with the target level. It automatically adjusts stimulation current to ensure consistent neural activation. The company focuses on neuromodulation solutions for chronic pain. It utilizes Evoked Compound Action Potentials to advance neuromodulation therapy.
- Oct 2025Series F$30M
- Jan 2025Series F$100M
- Apr 2023Series F$150M
- Mar 2022Series F$125M
#2
Public · Ashburn, Virginia · founded 1986 · 4 employees$106Mraised▾
Developer of small molecule-based therapeutics for the treatment of CNS and dermatology diseases. The company's lead product candidate QRX001 acts as an antagonist of the N-methyl-D-aspartate receptor (NMDA) and is used for the treatment of post-surgical pain. Another product of the company QRX002 which also acts as an NMDA receptor antagonist used for the treatment of suicidal ideation in military veterans with PTSD.
- Oct 2025Post IPO$105.3M
- Mar 2021Post IPO—
- Oct 2020Post IPO$710K
#3
Acquired · Cleveland, Ohio · founded 2008$180.3Mraised▾
Developer of non-implant peripheral nerve stimulation systems for pain management. This company provides a clinically proven, patient-preferred non-surgical option for managing chronic, intractable, post-surgical, post-traumatic, and post-operative pain. The system offers symptomatic relief and is indicated for up to 60 days of use. The most common adverse events are skin irritation and erythema. The company is focused on advancing non-opioid, non-surgical, minimally invasive pain management solutions.
- Mar 2025Grant (prize money)$6M
- Feb 2024Convertible Debt$60M
- Jan 2024Series D$25.6M
- Oct 2021Series D$37M
#4
Seed · Texas · founded 2023$6Mraised▾
Developer of non-invasive ultrasound neuromodulation platform for chronic inflammatory disorders. It focuses on stimulating the spleen-brain axis to control inflammation. The technology uses broad-beam ultrasound to activate nerves, releasing neurotransmitters that signal the immune system. This aims to restore immune balance and provide relief from inflammation. The platform is being developed to treat autoimmune disorders without drugs.
- Apr 2026Seed—
- Mar 2026Seed$6M
#5
Series D · Menlo Park, California · founded 2017 · 50 employees$101.9Mraised▾
Developer of drugs for post-surgical pain management. The company's proprietary technology platform combines non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site. The company's lead candidate is ATX-101 for post surgical knee rehabilitation. Other candidates include ATX-201 and ATX-301 injectables for on-demand delivery.
- Jun 2025Venture Debt—
- Jan 2025Series D$57.5M
- Dec 2022Series D—
- Sep 2021Series C$86.9M
#6
Public · Boston, Massachusetts · founded 2013 · 14 employees$65.7Mraised▾
Centrexion has developed non-opioid, non-surgical treatments for chronic pain management. The company's lead candidate CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic pain due to knee osteoarthritis (phase III). The other products include CNTX-0290 (somatostatin SSTR4 agonist) for pain (phase I), CNTX-6970 (cytokine CCR2 antagonist) to treat inflammatory pain (phase II), CNTX-2022 (lidocaine gel) to treat superficial pain (phase I), and CNTX-6016 (CB2 agonist) to treat neuropathic pain (phase I).
- May 2025Grant (prize money)$6.6M
- Jan 2025Grant (prize money)$6.6M
- Dec 2023Post IPO$3.3M
- Nov 2023Post IPO$2.3M
#7
Seed · Boston, Massachusetts · founded 2022$12.2Mraised▾
Developer of an optogenetic platform targeting pathological neural activity to restore balance. The platform precisely targets pathological neural activity when and where it occurs. It aims to restore equilibrium within the nervous system through targeted intervention.
- Nov 2025Seed$12.2M
#8
Series A · Oakdale, Minnesota · founded 2014 · 7 employees$8Mraised▾
Developer of multi-phase prolonged release drug delivery platform for localized treatments. The company focuses on developing drug delivery solutions for pain, cancer, and infection treatments. It utilizes technology to address unmet needs in pain management and drug delivery markets. The company's products include an extended-release pain control solution focused on peri-operative pain management and an early-development product focused on local delivery of cancer drugs with a precise elution rate over a pre-programmed period of time.
- Nov 2025Series A$4M
- Dec 2023Series A$3M
- Jun 2020Series A$5M
- Dec 2018Seed$2M
#9
Series B · Fairfield, Connecticut · founded 2002 · 7 employees$8.6Mraised▾
Provider of an analgesic product candidate, and polymer and hydrogel drug delivery platform technologies. The company's lead candidate Cyt-1010 is an analgesic for moderate to severe pain. Also, provides drug delivery technologies such as polymers and hydrogels to enhance the kinetic profiles of human drugs, as well as pharmacologic properties of veterinary medicines.
- Oct 2025Series B$250K
- Jun 2023Series B$1.8M
- May 2021Series A$956.9K
- Mar 2019Conventional Debt$100K
#10
Series A · San Francisco, California · founded 2013 · 2 employees$2.4Mraised▾
Developing innovative solutions to combat opioid overdose and reduce opioid abuse. This therapeutics company is dedicated to establishing new safety standards in the pharmaceutical industry, specifically addressing the opioid crisis. They focus on creating Safer Medicines that Alleviate Risks and Trauma (SMART) products. Their lead products include a rescue agent designed for synthetic opioid overdoses and an oral overdose protection system. These solutions aim to reduce opioid use disorder, prevent fatal overdoses, and effectively manage pain. The company leverages its expertise to develop novel chemical entities with the potential to receive breakthrough technology designation. They are seeking partners to support their mission of reducing suffering from pain, opioid use disorder, and fatal opioid overdose. Their work has a significant social impact, addressing a critical public health issue.
- Jan 2026Series A$7.5M
- Oct 2022Seed$2.2M
- Mar 2019Seed$215K
- Jun 2018Grant (prize money)$6.2M
#11
Funding Raised · Davis, California · founded 2011 · 14 employees$30.8Mraised▾
Developing safer pain and inflammation treatments by restoring the body's natural healing. The company is focused on transforming inflammation treatment with a novel approach. They are developing new safe and effective oral analgesics and anti-inflammatories by targeting the soluble Epoxide Hydrolase (sEH). This innovative technology aims to address the unmet need for non-addictive pain medications and combat the opioid crisis. The company is advancing its first drug candidate through human clinical trials. Their research explores the potential of sEH inhibitors for various conditions, including neuropathic pain, traumatic brain injury, and Alzheimer's disease. The company collaborates with researchers and institutions to advance scientific understanding and develop innovative therapies. They are committed to improving the lives of those suffering from pain and inflammation through scientific research and clinical development.
- Apr 2025Grant (prize money)$6.8M
- Jan 2025Grant (prize money)$6.8M
- Jul 2022Grant (prize money)$279.1K
- Oct 2019Grant (prize money)$15M
#12
Acquired · San Francisco, California · founded 2010$23.8Mraised▾
SiteOne Therapeutics is focussed on developing pain therapeutics for the treatment of acute and chronic pain. Its therapeutic candidates are selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Its lead product for the treatment of moderate to severe pain is in pre-clinical trials Its technology also has additional applications in long-acting analgesics, PET imaging diagnostics for pain and other pain indications.
- Apr 2025Grant (prize money)$1.5M
- Dec 2024Series C$100M
- Mar 2024Series B$6M
- May 2023Grant (prize money)$15M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Pain Management coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Medical Devices is moving in the United States
A read on the academic research around Medical Devices — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,830 United States-affiliated papers.
- Johns Hopkins University74
- United States Food and Drug Administration59
- Harvard University54
- Center for Devices and Radiological Health53
- Design Intelligence36
- Biocompatible material2→9
- Robotics7→13
- Health care1→6
- Tissue engineering1→5
- Automation1→5
- Health care2→24
- MEDLINE1→21
- Quality (philosophy)3→15
- Robotic surgery18→29
- Product (mathematics)5→16
- MEDLINE1→36
- Robotic surgery7→24
- Patient safety19→32
- Key (lock)6→19
- Quality (philosophy)10→20
Where medical devices is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing medical devices patents in the United States
United States medical devices patent filing is accelerating — 666,693 filings from 8,000 assignees (2016–2025), led by Covidien, Boston Scient Scimed, Medtronic; annual filings 63466→63610.
- Covidien29351
- Boston Scient Scimed24775
- Medtronic22434
- Becton Dickinson18269
- Procter & Gamble16210
- Ethicon ENDO Surgery13758
- Kimberly Clark12462
- Ethicon11769
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.